Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Did you experience any of the following side effects?
(Please check all that apply.)

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Risperdal Award Increased Over Delay Damages

Sep 16, 2016

In a recent Risperdal (risperidone) gynecomastia lawsuit, a Pennsylvania judge has agreed to increase a $70 million award to over $76 million.

The Risperdal gynecomastia lawsuit was filed against Johnson & Johnson's subsidiary, Janssen Pharmaceuticals, by a family on behalf of their teenage son. The boy, who took the antipsychotic drug Risperdal, allegedly began to develop breasts, a condition known as gynecomastia.

The additional $6.7 million award is meant to cover delay damages, given that the lawsuit took some time to settle on July 1, 2016. The family's counsel indicated that they were entitled to considerable delay damages. The family's wait took over one year after the complaint was served on April 16, 2014.

Janssen Pharmaceuticals argued that the demand was erroneous and a representative wrote that, "we continue to believe the verdict was not justified and should be reversed on appeal." Despite these claims, the Pennsylvania judge approved the additional Risperdal award.

The benefits of the possibility of delay damages are allowed, according to Pennsylvania rules and ensures that defendants do not profit by extending time before injured parties receive justice.

The Risperdal gynecomastia lawsuit alleged that the boy began taking Risperdal in 2003. Lawsuit allegations also include that the boy developed gynecomastia. When gynecomastia occurs, the abnormal growth of female-like breasts are comprised of breast tissue and not fat tissue, which means that medical intervention is needed to address the male breasts.

At the time the boy started treatment in 2003 with Risperdal, the drug was approved for the treatment of schizophrenia in adults. A warning label at that time did note that gynecomastia was a potential Risperdal side effect; however, the side effect was deemed rare.

The lawsuit alleged that Janssen scientists were aware, as far back as when the boy began taking Risperdal, that the drug was associated with increases in development of the hormone, prolactin, and that these prolactin increase might lead to the development of gynecomastia.

Now, hundreds of boys and young men who allege suffering from Risperdal gynecomastia have filed lawsuits against Johnson & Johnson. They allege that the drug maker neglected to appropriately warn patients and the medical community about the potential and significant side effects of Risperdal.

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo